Medtronic announces U.S. commercial launch of DBS
Medtronic announced both the U.S. launch of Deep Brain Stimulation, or DBS, for medically-refractory epilepsy and the first commercially implanted patient at Emory University in Atlanta, Georgia. According to the Epilepsy Foundation, as many as 3.4M Americans have epilepsy, with one-third estimated to be drug resistant. DBS therapy for epilepsy delivers controlled electrical pulses to a target in the brain called the anterior nucleus of the thalamus, or ANT, which is part of a network involved in seizures. Recently, the FDA granted pre-market approval for Medtronic DBS Therapy for Epilepsy as adjunctive treatment for reducing the frequency of partial-onset seizures in individuals 18 years of age or older who are refractory, or drug-resistant, to three or more antiepileptic medications. The approval was based on results from the SANTE trial, wherein patients had a median seizure frequency reduction of 75 percent at seven years post-implant.